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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1511Aortic StiffnessJoão L. Cavalcante, João A. C. Lima, Alban Redheuil, Mouaz Al-Mallah
The aorta stiffens with aging; the structural and functional degenerative changes are
accelerated by arterial hypertension and possibly other mechanisms. Cavalcante and colleagues
review the pathophysiology of aortic stiffness (AS), the various methods for assessing AS, and
the available clinical evidence regarding not only the risk factors for AS but the potential to
modulate the underlying processes with medical therapy.CLINICAL RESEARCH HEART FAILURE
1523Cardiomyocyte Hypertrophy, Oncosis, and
Autophagic Vacuolization in Patients With IDCMCarlos A. Vigliano, Patricia M. Cabeza Meckert, Mirta Diez, Liliana E. Favaloro, Claudia Cortés,
Lucı´a Fazzi, Roberto R. Favaloro, Rubén P. Laguens
Vigliano and colleagues reviewed endomyocardial biopsies from 100 patients with idiopathic
dilated cardiomyopathy (IDCM). Immunohistochemical methods and terminal
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling studies
determined the proportion of cardiomyocytes (CMs) with evidence of apoptosis, autophagic
vacuolization (AuV), and/or oncosis, which is the process of accidental cell death. AuV was
found in 28% of patients and oncosis in 41%; both processes were found in 19% of patients.
Evidence of apoptosis was rare. In multivariable analysis, CM diameter and simultaneous
presence of AuV and oncosis were independent predictors of mortality.
Editorial Comment: Sawa Kostin, p. 1532(continued on page A-23)
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ELIPID-LOWERING AND DIABETES1535Predictors of New-Onset Diabetes in Patients Treated With AtorvastatinDavid D. Waters, Jennifer E. Ho, David A. DeMicco, Andrei Breazna, Benoit J. Arsenault,
Chuan-Chuan Wun, John J. Kastelein, Helen Colhoun, Philip Barter
A recent meta-analysis concluded that statin therapy may modestly increase the risk of
new-onset type 2 diabetes (T2DM). Waters and colleagues used data from 3 large studies of
high-dose atorvastatin (80 mg) and found that compared with placebo, atorvastatin 80 mg
resulted in an absolute increase of 2.65% for new-onset T2DM. There were similar, but
nonsignificant, trends when atorvastatin 80 mg was compared with simvastatin 20 mg or
atorvastatin 10 mg. In each of the 3 trials, baseline fasting blood glucose, body mass index,
hypertension, and fasting triglycerides were independent predictors of new-onset T2DM.
These results confirm a slight increase in the risk of new-onset T2DM in patients treated
with high-dose atorvastatin, particularly in patients with baseline features of the metabolic
syndrome.HEALTH SERVICES RESEARCH1546Concordance of Physician Ratings With the AUC for Coronary RevascularizationPaul S. Chan, Ralph G. Brindis, David J. Cohen, Philip G. Jones, Elizabeth Gialde, Richard G. Bach,
Jeptha Curtis, Charles F. Bethea, Marc E. Shelton, John A. Spertus
The appropriate use criteria (AUC) for coronary revascularization were compiled by a
technical panel of 17 members who went through a structured review process. Prior to
publication of these criteria, Chan and colleagues asked 85 cardiologists to independently
review the same data that the technical panel did and rate the appropriateness of coronary
revascularization for several indications. While there was generally good concordance between
the 2 groups, more than 1 in 4 physicians assigned appropriateness ratings outside of the
group’s category for 66% of the indications. No surveyed physician had 80% agreement
ith the AUC.ditorial Comment: Paul T. Vaitkus, p. 1554HEALTH SERVICES RESEARCH: COMMENTARY1557The Privilege of Self-Regulation: The Role of AUCManesh R. Patel, Michael J. Wolk, Joseph Allen, Gregory J. Dehmer, Ralph G. Brindis
In their commentary regarding the paper by Chan and colleagues, which describes some
discrepancies between the views of practicing physicians and the American College of
Cardiology’s appropriate use criteria (AUC) for coronary revascularization, Patel and
colleagues describe key differences in the methodologies of the 2 groups but also take the
opportunity to emphasize 2 points about AUC. First, AUC are not static documents, but are
meant to undergo frequent updates and reassessments. Second, providers should not be
penalized for a small number of inappropriate procedures, but rather the AUC should be used
to identify outliers. The authors end by emphasizing that it is better for cardiologists
themselves to define optimal care rather than other parties with different vested interests.(continued on page A-28)
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The Department of Health and Human Services has recently published 25 criteria for
determination of “meaningful use” of electronic health records. Oetgen and colleagues argue
that 3 of the criteria—electronic clinical information exchange, clinical decision support rules,
and reporting clinical quality measures to the Centers for Medicare & Medicaid Services—
are transformational for the practice of medicine in America. They go on to describe how the
American College of Cardiology’s (ACC’s) and National Cardiovascular Data Registry’s
PINNACLE (Practical Innovation and Clinical Excellence) Registry and the ACC’s
appropriate use criteria will allow cardiologists to fulfill key meaningful use objectives.
